Overactive Bladder Treatment
All patients with OAB should begin with behavioral therapies (bladder training, fluid management, caffeine reduction), and when pharmacotherapy is needed, beta-3 agonists are preferred over antimuscarinics as first-line medication due to lower cognitive risks, particularly dementia. 1
Treatment Algorithm
First-Line: Behavioral Therapies (Offer to ALL Patients)
- Bladder training (most extensively studied and strongly recommended)
- Fluid management and caffeine reduction
- Physical activity/exercise
- Dietary modifications
- Mindfulness techniques
These have excellent safety profiles with minimal adverse effects, though success depends heavily on patient adherence 1. Behavioral therapies should be offered to all patients regardless of whether pharmacotherapy is initiated 1.
Second-Line: Pharmacotherapy
Beta-3 agonists (mirabegron, vibegron) should be tried BEFORE antimuscarinics due to the association between antimuscarinic medications and incident dementia, which appears cumulative and dose-dependent 1. A meta-analysis of 11 cohort studies and 3 case-control studies found antimuscarinics increased risk of all-cause dementia and Alzheimer's disease 1.
When to Use Antimuscarinics with Extreme Caution:
- Narrow-angle glaucoma
- Impaired gastric emptying
- History of urinary retention
- Diabetes, prior abdominal surgery, narcotic use, scleroderma, hypothyroidism, Parkinson's disease, multiple sclerosis 1
Critical counseling point: Discuss dementia and cognitive impairment risks with ALL patients prescribed antimuscarinics, regardless of age 1.
Both drug classes (antimuscarinics and beta-3 agonists) have Grade A evidence for improving urgency, frequency, and urgency urinary incontinence 1. Treatment choice should be based on side effect profiles through shared decision-making 1.
Combination Therapy
For inadequate response to monotherapy, combine behavioral therapy with pharmacotherapy, or layer multiple approaches 1. When combining more than two therapies, add them stepwise (not simultaneously) to determine individual impact of each therapy 1. Monitor for improvement and discontinue ineffective therapies 1.
Important: There is insufficient evidence for nutraceuticals, vitamins, supplements, or herbal remedies—do not recommend these 1.
Third-Line: Minimally Invasive Procedures
For patients with inadequate response to or intolerable side effects from pharmacotherapy/behavioral therapy, offer:
- Sacral neuromodulation (SNM)
- Tibial nerve stimulation (PTNS or implantable)
- Intradetrusor botulinum toxin injection (100 units)
This is a Moderate Recommendation with Grade A evidence 1.
Key Paradigm Shift:
Minimally invasive therapies may be offered WITHOUT requiring trials of behavioral or pharmacologic management in the context of shared decision-making 1. This represents a departure from strict stepwise progression, recognizing that:
- Long-term compliance with behavioral/pharmacotherapy is poor
- Minimally invasive options have high success rates, durable efficacy, and excellent patient satisfaction
- Many patients who would benefit never progress to these therapies due to frustration with failed conservative measures 1
All three minimally invasive options (SNM, PTNS, botulinum toxin) effectively reduce voiding frequency, nocturia, urgency episodes, and incontinence episodes 1.
Common Pitfalls to Avoid
- Starting antimuscarinics before beta-3 agonists without considering dementia risk
- Failing to assess post-void residual before starting antimuscarinics (risk of urinary retention)
- Not counseling about cognitive risks in elderly patients on chronic antimuscarinic therapy
- Delaying minimally invasive therapies in frustrated patients who have failed conservative measures—these can be offered earlier
- Recommending supplements/nutraceuticals—no adequate evidence exists 1
- Adding multiple therapies simultaneously—prevents determining which intervention is effective 1